Compare KWR & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KWR | EWTX |
|---|---|---|
| Founded | 1918 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.5B |
| IPO Year | 1985 | 2021 |
| Metric | KWR | EWTX |
|---|---|---|
| Price | $143.46 | $21.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $149.25 | $34.13 |
| AVG Volume (30 Days) | 136.7K | ★ 1.5M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.40% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,864,242,000.00 | N/A |
| Revenue This Year | $3.44 | N/A |
| Revenue Next Year | $4.15 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.08 | N/A |
| 52 Week Low | $95.91 | $10.60 |
| 52 Week High | $148.80 | $32.61 |
| Indicator | KWR | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.80 | 47.13 |
| Support Level | $136.34 | $20.14 |
| Resistance Level | $146.16 | $25.56 |
| Average True Range (ATR) | 4.45 | 1.74 |
| MACD | 0.77 | -0.38 |
| Stochastic Oscillator | 81.78 | 27.05 |
Quaker Houghton manufactures and sells a variety of industrial process fluids. The product portfolio of the company includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids and surface treatment chemicals. The geographic segments of the company include America, EMEA, Asia/Pacific, and Global Specialty Businesses. The majority of the revenue is earned from America.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.